Literature DB >> 22265076

Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand.

Adun Mohara1, Inthira Yamabhai, Kakanang Chaisiri, Sripen Tantivess, Yot Teerawattananon.   

Abstract

OBJECTIVES: To assess the budget impact of the government use licenses policy, a form of compulsory licensing used by the government, on seven patented drugs, namely, efavirenz, lopinavir/ritonavir combination, clopidogrel, letrozole, docetaxel, erlotinib, and imatinib, in Thailand between 2006 and 2008.
METHODS: By using government's perspective, budget impact was estimated within a 5-year period after the introduction of the policy. The number of patients who need treatment with each drug and the costs of treatments by both original and generic versions were obtained from Thai government agencies. Probabilistic sensitivity analysis was used to determine the impact of uncertainty surrounding parameters such as the numbers of patients and the health-care costs.
RESULTS: The study indicated that the use of generic drugs under the policy could save the government budget approximately $370 million over 5 years. It was also found that each drug had a different effect on budget saving depending on the number of patients treated, the difference in drug costs between original and generic drugs, and the lag time from the introduction of the policy to the availability of the generic drugs on the market.
CONCLUSION: The study showed that the introduction of the government use licenses policy in Thailand would provide significant benefits for the study timeframe; however, there are several issues that should be taken into account when the government use licenses policy is adopted.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265076     DOI: 10.1016/j.jval.2011.11.016

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  9 in total

Review 1.  Building the Case for Clopidogrel as a World Health Organization Essential Medicine.

Authors:  Amisha Patel; Mahesh Vidula; Sunny P Kishore; Rajesh Vedanthan; Mark D Huffman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-02

Review 2.  Access to cancer medications in low- and middle-income countries.

Authors:  Gilberto de Lima Lopes; Jonas A de Souza; Carlos Barrios
Journal:  Nat Rev Clin Oncol       Date:  2013-04-09       Impact factor: 66.675

Review 3.  What is the impact of intellectual property rules on access to medicines? A systematic review.

Authors:  Brigitte Tenni; Hazel V J Moir; Belinda Townsend; Burcu Kilic; Anne-Maree Farrell; Tessa Keegel; Deborah Gleeson
Journal:  Global Health       Date:  2022-04-15       Impact factor: 10.401

Review 4.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

5.  Expensive medicines: ensuring objective appraisal and equitable access.

Authors:  Suzanne R Hill; Lisa Bero; Geoff McColl; Elizabeth Roughead
Journal:  Bull World Health Organ       Date:  2015-01-01       Impact factor: 9.408

6.  Policies and programs to facilitate access to targeted cancer therapies in Thailand.

Authors:  Rosarin Sruamsiri; Dennis Ross-Degnan; Christine Y Lu; Nathorn Chaiyakunapruk; Anita K Wagner
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

Review 7.  Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?

Authors:  Cinthia Leite Frizzera Borges Bognar; Brittany L Bychkovsky; Gilberto de Lima Lopes
Journal:  J Glob Oncol       Date:  2016-06-29

8.  Defining the Benefit Package of Thailand Universal Coverage Scheme: From Pragmatism to Sophistication.

Authors:  Viroj Tangcharoensathien; Walaiporn Patcharanarumol; Waraporn Suwanwela; Somruethai Supangul; Warisa Panichkriangkrai; Hathairat Kosiyaporn; Woranan Witthayapipopsakul
Journal:  Int J Health Policy Manag       Date:  2020-04-01

Review 9.  TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.

Authors:  Shiri Mermelstein; Hilde Stevens
Journal:  Pharmaceutics       Date:  2021-12-27       Impact factor: 6.525

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.